- Home
- WHF vs DRUG Comparison
WHF vs DRUG Comparison
Compare WHF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- DRUG
- Stock Information
- Founded
- WHF 2011
- DRUG 2019
- Country
- WHF United States
- DRUG United States
- Employees
- WHF N/A
- DRUG N/A
- Industry
- WHF Finance Companies
- DRUG Pharmaceuticals and Biotechnology
- Sector
- WHF Finance
- DRUG Health Care
- Exchange
- WHF Nasdaq
- DRUG Nasdaq
- Market Cap
- WHF 226.2M
- DRUG 233.2M
- IPO Year
- WHF 2012
- DRUG N/A
- Fundamental
- Price
- WHF $9.31
- DRUG $32.06
- Analyst Decision
- WHF Sell
- DRUG Strong Buy
- Analyst Count
- WHF 4
- DRUG 5
- Target Price
- WHF $10.83
- DRUG $83.25
- AVG Volume (30 Days)
- WHF 68.2K
- DRUG 25.6K
- Earning Date
- WHF 05-12-2025
- DRUG 05-20-2025
- Dividend Yield
- WHF 16.54%
- DRUG N/A
- EPS Growth
- WHF N/A
- DRUG N/A
- EPS
- WHF 0.47
- DRUG N/A
- Revenue
- WHF $92,817,000.00
- DRUG N/A
- Revenue This Year
- WHF N/A
- DRUG N/A
- Revenue Next Year
- WHF N/A
- DRUG N/A
- P/E Ratio
- WHF $19.86
- DRUG N/A
- Revenue Growth
- WHF N/A
- DRUG N/A
- 52 Week Low
- WHF $8.44
- DRUG $0.93
- 52 Week High
- WHF $13.44
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- WHF 40.70
- DRUG 49.86
- Support Level
- WHF $9.27
- DRUG $29.02
- Resistance Level
- WHF $9.68
- DRUG $32.75
- Average True Range (ATR)
- WHF 0.18
- DRUG 2.17
- MACD
- WHF -0.02
- DRUG 0.01
- Stochastic Oscillator
- WHF 5.88
- DRUG 46.41
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate attractive risk-adjusted returns for investors, primarily by originating senior secured loans to privately held small-cap companies across a broad range of industries.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.